June 2015. Volume 11. Number 2

Displasia broncopulmonar y azitromicina, ¿una solución o un nuevo problema?

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

CA | Associated comment

Author: Sánchez Luna M1.
1Hospital General Universitario . Madrid. España.
Correspondence: Manuel Sánchez Luna. Email: msluna@salud.madrid.org
Reception date: 23/04/2015
Acceptance date: 29/04/2015
Publication date: 06/05/2015

CA | Associated comment

Author: Sánchez Luna M1.
1Hospital General Universitario . Madrid. España.
Correspondence: Manuel Sánchez Luna. Email: msluna@salud.madrid.org
Reception date: 23/04/2015
Acceptance date: 29/04/2015
Publication date: 06/05/2015

How to cite this article

Sánchez Luna M. Displasia broncopulmonar y azitromicina, ¿una solución o un nuevo problema? Evid Pediatr. 2015;11:32.

References

  1. Sánchez Luna M, Moreno Hernando J, Botet Mussons F, Fernández Lorenzo JR, Herranz Carrillo G, Rite Gracia S, et al. Comisión de Estándares de la Sociedad Española de Neonatología. Displasia broncopulmonar: definiciones y clasificación. An Pediatr (Barc). 2013;79:262.e1-6.
  2. García-Muñoz Rodrigo F, Díez Recinos AL, García-Alix Pérez A, Figueras Aloy J, Vento Torres M. Changes in perinatal care and outcomes in newborns at the limit of viability in Spain: the EPI-SEN Study. Neonatology. 2015;107:120-9.
  3. Ballard HO, Shook LA, Bernard P, Anstead MI, Kuhn R, Whitehead V, et al. Use of azithromycin for the prevention of bronchopulmonary dysplasia in preterm infants: a randomized, double-blind, placebo controlled trial.Pediatr Pulmonol. 2011;46:111-8.
  4. 4 Kenyon SL, Taylor DJ, Tarnow-Mordi W; ORACLE Collaborative Group. Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomized trial. ORACLE Collaborative Group. Lancet. 2001;357:979-88. Erratum en: Lancet 2001;358:156.
  5. Lyon AJ, McColm J, Middlemist L, Fergusson S, McIntosh N, Ross PW. Randomised trial of erythromycin on the development of chronic lung disease in preterm infants. Arch Dis Child Fetal Neonatal Ed. 1998;78:F10-4.

Related Articles

AVC | Prophylactically administered azitrhomycin could modestly reduce the incidence of bronchopulmonary dysplasia

Perdikidi Olivieri L, Buñuel Álvarez JC. La azitromicina administrada de forma profiláctica podría reducir moderadamente la incidencia de displasia broncopulmonar. Evid Pediatr. 2015;11:29.
06/05/2015

Linked Comment